Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and...
Company Valuation
Based on key historical and expected multiples, the stock is slightly overvalued relative to its peers. In particular, the stock is reasonably priced on P/E.
Target Price
The average target price of ESPR is 7.3 and suggests 196% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increa
Buy
Sell